Truist Securities still thinks Agios Pharmaceuticals is a good buy but has cut its price target to $35.

AGIO · Agios Pharmaceuticals, Inc.

The AI's read

The note gives two different signals: Truist still rates Agios Buy, but lowered its target. It follows recent financial disclosures without describing new company results, so it does not show a clear change in Agios's business outlook.